Glaucoma Research
Participation in ophthalmic research and innovation is an integral part of clinical practice at Ophthalmology Associates. Brian Flowers, M.D. has led an FDA clinical research facility focused on Glaucoma for many years. More cutting-edge, innovative medical and surgical treatments for glaucoma are available here than most major medical academic centers. Research and innovation enhance patient care and allow us to give back to our patients and society. Because of our excellent glaucoma care, we are sought after for participation in most new projects. However, we are very selective regarding which studies we participate in. We carefully review the evidence that supports the innovation in question. The surgery or medication is often already approved in Europe and/or Canada yet unavailable in the US. This often allows us to evaluate years of experience with a procedure before offering it to our patients.
Patients may choose to participate in studies on new medications, new methods of administering medication to avoid the need for eyedrops, and minimally invasive glaucoma surgeries. We are proud to have helped usher in groundbreaking procedures such as canaloplasty, CyPass, and iStents, with many others soon to come.
Patients are evaluated for our research studies during their regular office visits. Our doctors will let patients know if they qualify for a particular study. Patients are typically eager to participate, as the benefits of being a study candidate are many, including receiving new innovative treatment and reduced cost of care.
Most patients receive a stipend for participating in studies, and the study sponsor often covers the cost of office visits. If you are interested in participating, please call our office and ask to speak with our research coordinator.
Current and Ongoing Research Studies
Eligibility Information
For more information about whether you are an eligible candidate for a research study, talk to your doctor, call the glaucoma research department at Ophthalmology Associates in Fort Worth at 817-332-2020, or use the form below.
CLINICAL TRIALS Clinical Trials
Currently Enrolling Clinical Trials
- Randomized Study of the Safety and Effectiveness of the Sight Sciences VISCO™360 Viscosurgical System Versus SLT in Primary Open Angle Glaucoma (VISCO360 Study) [Protocol SIGHTVISCO-001] Sponsor: Sight Sciences, Inc.
- The Hydrus microstent for Refractory Open-Angle Glaucoma: A Prospective, Multicenter Clinical Trial [Protocol CP 16-001]
Sponsor: Ivantis, Inc. - A Prospective, Randomized, Controlled, Parallel Groups, Multicenter Clinical Investigation of the Glaukos® Trabecular Micro-Bypass System Model G2-W vs. Selective Laser Trabeculoplasty [GC-004]
Sponsor: Glaukos Corp.
Past Clinical Trials
- A Prospective, Randomized, Single-Masked, Controlled, Parallel Groups, Multicenter Clinical Investigation of the Glaukos® Trabecular Micro-Bypass Stent Model GTS400 using the G@-M-IS Injector System in Conjunction with Cataract Surgery [GC-008]
Sponsor: Glaukos Corp. - A Randomized Study Comparing the Safety and Efficacy of the InnFocus MicroShuntTM Glaucoma Drainage System to Standard Trabeculectomy in Subjects with Primary Open Angle Glaucoma [Protocol INN-005]
Sponsor: InnFocus, Inc. - A Prospective, Randomized, Single-Masked, Comparative, Multicenter Clinical Study to Assess the Safety and Effectiveness of the Transcend CyPass Glaucoma Implant in Patients with Open-Angle Glaucoma Undergoing Cataract Surgery (COMPASS Study) [TMI-09-01 Extension]
Sponsor: Transcend/Alcon - The Safety and Effectiveness of the Hydrus Aqueous Implant for Lowering Intraocular Pressure in Glaucoma Patients Undergoing Cataract Surgery, A Prospective, Multicenter, Randomized, Controlled Clinical Trial (Hydrus 4 Study) [Protocol CP 11-001]
Sponsor: Ivantis Inc. - A Phase 2 Prospective, Multicenter, Randomized, Double-Masked Clinical Trial to Evaluate the Safety, Efficacy, and Dose-Response of the Bimatoprost Ocular Insert (2.2 mg, 13 mg) and Timolol (0.5%) Topical Ophthalmic Solution in Patients with Open-Angle Glaucoma or Ocular Hypertension
Sponsor: ForSight VISION 5, Inc. - A Prospective, Double-Masked, Randomized, Multi-Center, Active-Controlled, Parallel Group 12-month Study Assessing the Safety and Ocular Hypotensive Efficacy of PG324 Ophthalmic Solution Compared to AR-13324 Ophthalmic Solution, 0.02% and Latanoprost Ophthalmic Solution, 0.005% in Subjects with Elevated Intraocular Pressure [Protocol PG324-CS301 Mercury 1]
Sponsor: Aerie Pharmaceuticals, Inc. - Alcon C-00-50 Phase IV Travatan in African Americans
- Allergan Mementine Phase III
- Alcon C-01-69 Phase III, Travatan/Timolol vs Travatan
- Alcon C-01-70 Phase III, Travatan/Timolol vs Travatan
- Allergan internet study
- Alcon ORA study
- Alcon Travalert C-04-69
- Pfizer Xalacom US Phase II